Elicio Therapeutics(ELTX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ELTX Elicio Therapeutics

盘前交易 10-26 09:13:14 EDT

1.90

-0.04

-2.06%

盘前1.83

-0.07-3.68%

07:35 EDT

最高1.98	最低1.79	成交量46.41万
今开1.94	昨收1.94	日振幅9.79%
总市值5,147万	流通市值3,803万	总股本2,709万
成交额87.64万	换手率2.32%	流通股本2,001万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ELTX","market":"US","secType":"STK","nameCN":"Elicio Therapeutics","latestPrice":1.9,"timestamp":1792785600000,"preClose":1.94,"halted":0,"volume":464094,"hourTrading":{"tag":"盘前","latestPrice":1.83,"preClose":1.9,"latestTime":"07:35 EDT","volume":1216,"amount":2410.679872,"timestamp":1793014554692,"change":-0.07,"changeRate":-0.036842,"amplitude":0.084211},"delay":0,"changeRate":-0.020618556701030948,"floatShares":20014300,"shares":27091187,"eps":-2.172087,"marketStatus":"盘前交易","change":-0.04,"latestTime":"10-26 09:13:14 EDT","open":1.94,"high":1.98,"low":1.79,"amount":876384.6210756,"amplitude":0.097938,"askPrice":2.33,"askSize":100,"bidPrice":1.3,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.172087,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793021400000},"marketStatusCode":1,"adr":0,"listingDate":1612501200000,"exchange":"NASDAQ","adjPreClose":1.9,"preHourTrading":{"tag":"盘前","latestPrice":1.83,"preClose":1.9,"latestTime":"07:35 EDT","volume":1216,"amount":2410.679872,"timestamp":1793014554692,"change":-0.07,"changeRate":-0.036842,"amplitude":0.084211},"postHourTrading":{"tag":"盘后","latestPrice":1.9,"preClose":1.9,"latestTime":"19:30 EDT","volume":505,"amount":957.16,"timestamp":1792798204934,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.3701203041219314,"impliedVol":0.6824,"impliedVolPercentile":0.12},"requestUrl":"/m/hq/s/ELTX","defaultTab":"news","newsList":[{"id":"1147998742","title":"Elicio Therapeutics 研究计划招募20名可切除或临界可切除胰腺癌患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1147998742","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147998742?lang=zh_cn&edition=full","pubTime":"2026-08-10 20:06","pubTimestamp":1786363563,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics 宣布，一项新研究预计将招募20名患者——这些患者均患有可切除或临界可切除的胰腺导管腺癌（Pdac）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197265800","title":"Elicio Therapeutics宣布启动研究者发起的Eli-002 7P新辅助疗法治疗胰腺导管腺癌的1期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1197265800","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197265800?lang=zh_cn&edition=full","pubTime":"2026-08-10 20:02","pubTimestamp":1786363332,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics正式宣布，其由研究者发起的Eli-002 7P新辅助疗法用于治疗胰腺导管腺癌的1期临床研究已正式启动。这一里程碑式的进展，标志着在攻克胰腺导管腺癌这一难治性疾病的道路上，迈出了关键一步。该研究旨在评估Eli-002 7P作为新辅助治疗方案的安全性和初步疗效，为患者带来新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELTX","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117239778","title":"Elicio Therapeutics 报告在 Eli-002 7P 治疗及后续检查点抑制剂联合疗法后，转移性 mKRAS 胰腺癌患者出现多例完全缓解","url":"https://stock-news.laohu8.com/highlight/detail?id=1117239778","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117239778?lang=zh_cn&edition=full","pubTime":"2026-06-17 20:06","pubTimestamp":1781698008,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics 宣布，其针对转移性 mKRAS 胰腺癌的 Eli-002 7P 疗法，联合后续的检查点抑制剂治疗，已观察到多例患者达到完全缓解。这一积极数据展现了该组合疗法在应对这一难治性癌症方面的潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ELTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161150044","title":"Elicio Therapeutics：两例患者维持完全缓解至少八个月，其中一例超13个月","url":"https://stock-news.laohu8.com/highlight/detail?id=1161150044","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161150044?lang=zh_cn&edition=full","pubTime":"2026-06-17 20:03","pubTimestamp":1781697824,"startTime":"0","endTime":"0","summary":"生物技术公司Elicio Therapeutics宣布，其研究性疗法在临床试验中取得积极进展。数据显示，有两名患者在接受治疗后维持了完全缓解状态，持续时间均至少达到八个月。其中一位患者的完全缓解期更是超过了十三个月，展现了该疗法持久的潜在疗效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","ELTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121705863","title":"Elicio Therapeutics：在传统对检查点抑制剂有反应的MSS/MMR-p患者中观察到完全缓解","url":"https://stock-news.laohu8.com/highlight/detail?id=1121705863","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121705863?lang=zh_cn&edition=full","pubTime":"2026-06-17 20:02","pubTimestamp":1781697766,"startTime":"0","endTime":"0","summary":"生物技术公司Elicio Therapeutics宣布，其疗法在微卫星稳定/错配修复功能缺陷（MSS/MMR-p）患者群体中观察到了完全缓解。这一患者群体历史上曾对检查点抑制剂产生过治疗反应，此次数据为针对该难治性癌症类型的免疫疗法带来了新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ELTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102846553","title":"Elicio Therapeutics公布三例患者在接受Eli-2 7P与纳武利尤单抗联合治疗后获得100%确认的完全缓解","url":"https://stock-news.laohu8.com/highlight/detail?id=1102846553","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102846553?lang=zh_cn&edition=full","pubTime":"2026-06-17 20:02","pubTimestamp":1781697749,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics 宣布，在三位患者接受其候选药物Eli-2 7P与纳武利尤单抗的联合疗法后，观察到了100%确认的完全缓解。这一积极数据为该公司在肿瘤免疫治疗领域的研发进展提供了有力支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","ELTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114316241","title":"Elicio Therapeutics盘中暴跌50% 中期胰腺癌疗法数据公布后股价重挫","url":"https://stock-news.laohu8.com/highlight/detail?id=1114316241","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114316241?lang=zh_cn&edition=full","pubTime":"2026-06-15 20:15","pubTimestamp":1781525716,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics的股价在盘前交易时段遭遇腰斩，暴跌幅度高达50%。这一剧烈波动紧随公司公布其处于研发中期的实验性胰腺癌疗法最新临床数据之后。市场对此份数据的反应极为负面，投资者信心遭受重创，导致股价在正式开盘前便大幅下挫。胰腺癌作为治疗难度极高的癌症类型，其新疗法的研发进展一直备受市场关注，而此次数据未能达到投资者预期，引发了大规模的抛售。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","ELTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110541924","title":"Elicio Therapeutics旗下Amplify-7P二期研究未达到意向治疗人群的主要无病生存期终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1110541924","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110541924?lang=zh_cn&edition=full","pubTime":"2026-06-15 19:06","pubTimestamp":1781521589,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics公司宣布，其针对Amplify-7P项目进行的二期临床试验，在预先设定的意向治疗人群分析中，未能达到主要终点指标——无病生存期。这一结果标志着该候选疗法的关键临床开发遭遇挫折。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","ELTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190540473","title":"Elicio Therapeutics 将聚焦于R0切除人群开展3期开发，并增加Eli-2 7P给药方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1190540473","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190540473?lang=zh_cn&edition=full","pubTime":"2026-06-15 19:02","pubTimestamp":1781521337,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics宣布，其3期临床试验的开发策略将进一步聚焦于R0切除后的患者群体，并计划增加Eli-2 7P的给药方案。这一调整旨在更精准地评估该疗法在特定人群中的疗效与安全性，标志着公司临床开发路径的重要演进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","ELTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111305718","title":"Elicio Therapeutics 公布Amplify-7P二期研究结果并阐述Eli-002 7P在胰腺癌辅助治疗中的三期开发策略","url":"https://stock-news.laohu8.com/highlight/detail?id=1111305718","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111305718?lang=zh_cn&edition=full","pubTime":"2026-06-15 19:01","pubTimestamp":1781521275,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics 公布了其Amplify-7P二期研究的最新数据，并详细阐述了针对Eli-002 7P在胰腺癌辅助治疗领域的精炼后三期临床开发策略。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516065459","title":"Elicio Therapeutics, Inc.盘中异动 快速下挫6.02%报7.81美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516065459","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516065459?lang=zh_cn&edition=full","pubTime":"2025-03-04 02:08","pubTimestamp":1741025317,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日02时08分，Elicio Therapeutics, Inc.股票出现异动，股价大幅跳水6.02%。Elicio Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.18%。Elicio Therapeutics, Inc.公司简介：Elicio Therapeutics Inc 是一家临床阶段的生物技术公司，致力于为治疗选择有限且结果不佳的患者开发癌症免疫疗法。Elicio 正在为一系列侵袭性癌症设计靶向淋巴结的 AMPlifiers、免疫调节剂、佐剂和疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304020837abe6733b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304020837abe6733b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4007","ELTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516379751","title":"Elicio Therapeutics, Inc.盘中异动 早盘大幅拉升5.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516379751","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516379751?lang=zh_cn&edition=full","pubTime":"2025-02-28 23:10","pubTimestamp":1740755402,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日23时10分，Elicio Therapeutics, Inc.股票出现异动，股价快速上涨5.68%。Elicio Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.44%。Elicio Therapeutics, Inc.公司简介：Elicio Therapeutics Inc 是一家临床阶段的生物技术公司，致力于为治疗选择有限且结果不佳的患者开发癌症免疫疗法。Elicio 正在为一系列侵袭性癌症设计靶向淋巴结的 AMPlifiers、免疫调节剂、佐剂和疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228231002a2580afc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228231002a2580afc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4007","ELTX","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514018228","title":"Elicio Therapeutics, Inc.盘中异动 急速上涨7.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514018228","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514018228?lang=zh_cn&edition=full","pubTime":"2025-02-25 22:57","pubTimestamp":1740495451,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日22时57分，Elicio Therapeutics, Inc.股票出现波动，股价大幅上涨7.89%。Elicio Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.07%。Elicio Therapeutics, Inc.公司简介：Elicio Therapeutics Inc 是一家临床阶段的生物技术公司，致力于为治疗选择有限且结果不佳的患者开发癌症免疫疗法。Elicio 正在为一系列侵袭性癌症设计靶向淋巴结的 AMPlifiers、免疫调节剂、佐剂和疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225225731abdc8476&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225225731abdc8476&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ELTX","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513477855","title":"Elicio Therapeutics, Inc.盘中异动 早盘股价大跌5.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513477855","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513477855?lang=zh_cn&edition=full","pubTime":"2025-02-24 23:15","pubTimestamp":1740410110,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日23时15分，Elicio Therapeutics, Inc.股票出现异动，股价急速下跌5.21%。Elicio Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.46%。Elicio Therapeutics, Inc.公司简介：Elicio Therapeutics Inc 是一家临床阶段的生物技术公司，致力于为治疗选择有限且结果不佳的患者开发癌症免疫疗法。Elicio 正在为一系列侵袭性癌症设计靶向淋巴结的 AMPlifiers、免疫调节剂、佐剂和疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022423151198910089&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022423151198910089&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","ELTX","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513629117","title":"Elicio Therapeutics, Inc.盘中异动 股价大涨6.79%报8.65美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513629117","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513629117?lang=zh_cn&edition=full","pubTime":"2025-02-21 23:09","pubTimestamp":1740150582,"startTime":"0","endTime":"0","summary":"北京时间2025年02月21日23时09分，Elicio Therapeutics, Inc.股票出现异动，股价快速拉升6.79%。Elicio Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.14%。Elicio Therapeutics, Inc.公司简介：Elicio Therapeutics Inc 是一家临床阶段的生物技术公司，致力于为治疗选择有限且结果不佳的患者开发癌症免疫疗法。Elicio 正在为一系列侵袭性癌症设计靶向淋巴结的 AMPlifiers、免疫调节剂、佐剂和疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221230942988de732&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221230942988de732&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LENZ","ELTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511461563","title":"Elicio Therapeutics, Inc.盘中异动 大幅拉升5.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511461563","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511461563?lang=zh_cn&edition=full","pubTime":"2025-02-15 02:14","pubTimestamp":1739556867,"startTime":"0","endTime":"0","summary":"北京时间2025年02月15日02时14分，Elicio Therapeutics, Inc.股票出现波动，股价大幅上涨5.33%。Elicio Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.54%。Elicio Therapeutics, Inc.公司简介：Elicio Therapeutics Inc 是一家临床阶段的生物技术公司，致力于为治疗选择有限且结果不佳的患者开发癌症免疫疗法。Elicio 正在为一系列侵袭性癌症设计靶向淋巴结的 AMPlifiers、免疫调节剂、佐剂和疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021502142896234e44&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021502142896234e44&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","ELTX","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510286325","title":"Elicio Therapeutics, Inc.盘中异动 早盘股价大涨6.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510286325","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510286325?lang=zh_cn&edition=full","pubTime":"2025-02-10 22:31","pubTimestamp":1739197902,"startTime":"0","endTime":"0","summary":"北京时间2025年02月10日22时31分，Elicio Therapeutics, Inc.股票出现波动，股价快速拉升6.58%。Elicio Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.38%。Elicio Therapeutics, Inc.公司简介：Elicio Therapeutics Inc 是一家临床阶段的生物技术公司，致力于为治疗选择有限且结果不佳的患者开发癌症免疫疗法。Elicio 正在为一系列侵袭性癌症设计靶向淋巴结的 AMPlifiers、免疫调节剂、佐剂和疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210223142a240a1e4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210223142a240a1e4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ELTX","BK4139","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508869142","title":"Elicio Therapeutics, Inc.盘中异动 急速下挫7.09%报8.65美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2508869142","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2508869142?lang=zh_cn&edition=full","pubTime":"2025-02-03 23:12","pubTimestamp":1738595549,"startTime":"0","endTime":"0","summary":"北京时间2025年02月03日23时12分，Elicio Therapeutics, Inc.股票出现波动，股价急速跳水7.09%。Elicio Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.62%。Elicio Therapeutics, Inc.公司简介：Elicio Therapeutics Inc 是一家临床阶段的生物技术公司，致力于为治疗选择有限且结果不佳的患者开发癌症免疫疗法。Elicio 正在为一系列侵袭性癌症设计靶向淋巴结的 AMPlifiers、免疫调节剂、佐剂和疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250203231229987975c2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250203231229987975c2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LENZ","ELTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507034965","title":"Elicio Therapeutics, Inc.盘中异动 早盘快速下跌5.63%报8.89美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2507034965","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2507034965?lang=zh_cn&edition=full","pubTime":"2025-01-31 22:38","pubTimestamp":1738334306,"startTime":"0","endTime":"0","summary":"北京时间2025年01月31日22时38分，Elicio Therapeutics, Inc.股票出现波动，股价大幅下跌5.63%。Elicio Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.65%。Elicio Therapeutics, Inc.公司简介：Elicio Therapeutics Inc 是一家临床阶段的生物技术公司，致力于为治疗选择有限且结果不佳的患者开发癌症免疫疗法。Elicio 正在为一系列侵袭性癌症设计靶向淋巴结的 AMPlifiers、免疫调节剂、佐剂和疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250131223826a23543af&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250131223826a23543af&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LENZ","ELTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507353621","title":"Elicio Therapeutics, Inc.盘中异动 股价大跌15.98%报8.10美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2507353621","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2507353621?lang=zh_cn&edition=full","pubTime":"2025-01-30 22:32","pubTimestamp":1738247527,"startTime":"0","endTime":"0","summary":"北京时间2025年01月30日22时32分，Elicio Therapeutics, Inc.股票出现异动，股价急速跳水15.98%。Elicio Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.28%。Elicio Therapeutics, Inc.公司简介：Elicio Therapeutics Inc 是一家临床阶段的生物技术公司，致力于为治疗选择有限且结果不佳的患者开发癌症免疫疗法。Elicio 正在为一系列侵袭性癌症设计靶向淋巴结的 AMPlifiers、免疫调节剂、佐剂和疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250130223207a2345521&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250130223207a2345521&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LENZ","ELTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.elicio.com","stockEarnings":[{"period":"1week","weight":0.2179},{"period":"1month","weight":0.016},{"period":"3month","weight":-0.3667},{"period":"6month","weight":-0.8375},{"period":"1year","weight":-0.8},{"period":"ytd","weight":-0.7613}],"compareEarnings":[{"period":"1week","weight":-0.0043},{"period":"1month","weight":-0.0102},{"period":"3month","weight":0.0285},{"period":"6month","weight":0.0645},{"period":"1year","weight":0.1313},{"period":"ytd","weight":0.1145}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Elicio Therapeutics Inc于1998年4月6日在特拉华州成立。该公司是一家临床阶段的生物技术公司，开发用于治疗癌症和疾病的新型免疫疗法管道。通过结合免疫学和免疫疗法方面的专业知识，Elicio正在设计研究性两亲（AMP）免疫疗法，旨在精确靶向并充分接合淋巴结。Elicio正在为一系列侵袭性癌症和传染病设计淋巴结靶向放大器、免疫调节剂、佐剂和疫苗。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":0.025227},{"month":2,"riseRate":0.2,"avgChangeRate":0.020436},{"month":3,"riseRate":0.5,"avgChangeRate":0.087379},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.052623},{"month":5,"riseRate":0.833333,"avgChangeRate":0.199324},{"month":6,"riseRate":0.166667,"avgChangeRate":-0.268302},{"month":7,"riseRate":0.5,"avgChangeRate":0.002708},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.063936},{"month":9,"riseRate":0.5,"avgChangeRate":-0.025161},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.158485},{"month":11,"riseRate":0.4,"avgChangeRate":-0.034248},{"month":12,"riseRate":0.4,"avgChangeRate":-0.005753}],"exchange":"NASDAQ","name":"Elicio Therapeutics","nameEN":"Elicio Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Elicio Therapeutics(ELTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Elicio Therapeutics(ELTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Elicio Therapeutics,ELTX,Elicio Therapeutics股票,Elicio Therapeutics股票老虎,Elicio Therapeutics股票老虎国际,Elicio Therapeutics行情,Elicio Therapeutics股票行情,Elicio Therapeutics股价,Elicio Therapeutics股市,Elicio Therapeutics股票价格,Elicio Therapeutics股票交易,Elicio Therapeutics股票购买,Elicio Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Elicio Therapeutics(ELTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Elicio Therapeutics(ELTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}